Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 11, 2009

Mepha to Distribute Debiopharm's Prostate Cancer Drug in Switzerland

Mepha to Distribute Debiopharm's Prostate Cancer Drug in Switzerland

Mepha and Debiopharm agree to distribute prostate treatment in Switzerland

  • Debiopharm says that Mepha Pharma will distribute three formulations of Pamorelin LA in Switzerland, which are developed for the treatment of prostate cancer, endometriosis, and female infertility.

    The agreement includes one-, three-, and six-month formulations of the drug containing triptorelin pamoate, a luteinizing hormone-releasing hormone agonist. The one- and three-month sustained-release formulations are marketed in the U.S. under the name Trelstar and as Decapeptyl and Pamorelin in Europe.

    The six-month formulation is expected to be submitted to Swiss regulatory officials in the third quarter, according to Debiopharm. The firm has already applied for U.S. and European approval of this formulation.

    Sales for the compound in China, Germany, the U.K., and other markets by Ipsen were €61.4 million in the first quarter, up 0.9% from 2008.ADNFCR-2184-ID-19162536-ADNFCR


    Past News from Debiopharm

    Aurigene to Assist with Advancement of Debiopharm’s Oncology Compound (Nov. 20, 2008)
    Pharmaleads to Assist with Development of Debiopharm’s Chronic Pain Therapeutic (Nov. 17, 2008)
    Debiopharm and EPFL Collaborate to Research New Cancer Treatments (Sep. 2, 2008)
    Debiopharm Receives cGMP Certification for QC of Drug Products (Sep. 11, 2007)
    Debiopharm Signs Four International Marketing Agreements for EVB Drug (Oct. 23, 2006)

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »